Boston Scientific to sell off its investment portfolio for $140M

  
Boston Scientific seeks to raise needed funds by selling its investment portfolio. Source: St. Louis Commerce Magazine 
Boston Scientific has elected to sell pieces of its investment portfolio in two transactions for a total of $140 million.

The company said that the sale is intended raise cash and reduce debt from its $27 billion acquisition of Guidant two years ago.

Saints Capital, a San Francisco-based investment company, bought holdings in a portfolio of 54 companies from the Natick, Mass.-based Boston Scientific for $100 million before taxes. In another transaction, private equity firm Paul Capital Partners bought Boston Scientific’s investments in a portfolio of venture funds and companies for $40 million.

In other cost-cutting measures, in October 2007, Boston Scientific announced plans to cut 2,300 jobs, or 8 percent of its work force, to help reduce annual operating expenses by $500 million.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.